This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Rohto Pharmaceutical Co., Ltd.. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2023
Title: Innovations by Yoshifumi Ikeyama
Introduction
Yoshifumi Ikeyama is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of mesenchymal stem cell research. With a total of 2 patents, his work focuses on developing novel therapeutic methods for various diseases.
Latest Patents
Ikeyama's latest patents include innovative methods related to ROR1-positive mesenchymal stem cells. These patents encompass a pharmaceutical composition containing ROR1-positive mesenchymal stem cells and methods for preparing them. The objective of his inventions is to provide mesenchymal stem cells that demonstrate superior therapeutic effects against various diseases. The ROR1-positive mesenchymal stem cells are characterized by specific cell surface markers, including CD29, CD73, CD90, CD105, and CD166, and are derived from umbilical cord or adipose tissue.
Career Highlights
Yoshifumi Ikeyama is associated with Rohto Pharmaceutical Co., Ltd., where he continues to advance his research in stem cell therapy. His work has the potential to revolutionize treatment options for patients suffering from various ailments.
Collaborations
Ikeyama collaborates with esteemed colleagues, including Masayo Yumoto and Xuan Trung Ngo, to further enhance the impact of his research.
Conclusion
Yoshifumi Ikeyama's innovative work in mesenchymal stem cells positions him as a key figure in the field of regenerative medicine. His contributions are paving the way for new therapeutic approaches to treat diseases effectively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile